Kuehn Law, PLLC is investigating whether officers and directors of Rhythm Pharmaceuticals, Inc. breached their fiduciary duties through potential self-dealing. The investigation could lead to damages for shareholders and reforms in corporate governance. Long-term shareholders are encouraged to contact the law firm for a free consultation, as there may be limited time to take action. This legal scrutiny highlights concerns about management integrity and shareholder rights at Rhythm Pharmaceuticals.
SK Hynix has approved a $38 billion investment to build new memory fabrication plants. However, these new fabs are not expected to produce any chips before December 2028, indicating a long-term expansion plan. This move highlights SK Hynix's commitme...
Anthropic CEO Dario Amodei responded to criticism that his warnings about AI risks have fueled negative public sentiment and regulatory backlash in the U.S. He argued his messaging has been balanced between AI's risks and benefits, emphasizing that p...
A $500 monthly investment split across three ETFs—Vanguard S&P 500 ETF (VOO), Schwab U.S. Dividend Equity ETF (SCHD), and Invesco NASDAQ 100 ETF (QQQM)—leverages diversification, dividend reinvestment, and growth to build wealth over decades. VOO off...
Walmart reports earnings Thursday amid concerns that U.S. comparable sales may miss expectations, with Oppenheimer downgrading the stock due to slower growth in General Merchandise and Health & Wellness. Target and Home Depot earnings earlier in the ...
Ethereum is integrating Bitcoin-inspired UTXO structures with its existing account model to tackle blockchain scaling challenges. This hybrid approach could reduce Ethereum's permanent payment-state storage by 99.8%, shrinking it from over 100 GB to ...
